Roche wont lower Avastin price despite NICE ruling

Posted on August 15, 2008 by crimsoncanary

Roche have issued a statement saying it won’t lower the price for Avastin despite UK’s NICE ruling that it is not a cost-effective treatment for advanced and/or metastatic renal cell carcinoma. Roche argue that Avastin is used in many cancer types and is fully reimbursed in most European countries.

Pfizer, Bayer and Wyeth are still considering their formal response.

Filed under: kinase | Tagged: , , , , , , ,

« Abbott publish series of COT kinase inhibitors Amgen researchers publish discovery of RON/cMet kinase inhibitor »